Skip to content
Review

Phage therapy for bacterial infections of CNS: a pharmacotherapeutic perspective.

Oct 2026 · Folia Microbiologica (Prague) · 0 citations · 69 references
Medicine

TL;DR

Today, owing to its targeted action, adequate tissue distribution and autodosing, phage therapy can serve as an ideal option for addressing hard-to-treat CNS infections caused by antibiotic resistant bacteria, despite of its challenging pharmacokinetics and formulation development.

View source

Similar papers

Review Open access Sep 2026

Bridging the gap between experimental evidence and clinical applications of antipseudomonal phage therapy against Pseudomonas aeruginosa.

Pseudomonas aeruginosa is one of the World Health Organization's (WHO) priority pathogens requiring urgent intervention because of its remarkable ability to develop antimicrobial resistance. The rapid emergence and global dissemination of multidrug-resistant P. aeruginosa have made the treatment of these infections inc...

Ahmed Elfadadny, W. Nageeb, Rokaia F. Ragab et al. · 0 citations
Review Open access Oct 2026

Combining Phages with Antibiotics as a Therapeutic Strategy for Managing Pseudomonas aeruginosa Pulmonary Infections: A Narrative Review of Preclinical and Clinical Evidence

Pseudomonas aeruginosa is an opportunistic Gram-negative bacillus responsible for several infectious conditions, including ventilator-associated pneumonia, acute pneumonia, and chronic pulmonary infections. The emergence and spread of antibiotic-resistant strains represent a major public health concern, particularly in...

Bárbara Rafaela Ferreira Aio, Gustavo Aparecido da Cunha, L. C. Malaquias et al. · 0 citations
Open access Sep 2026

Co-infection models of Staphylococcus aureus and respiratory viruses reveal synergistic interactions counteracted by a bithiazole derivative

The bithiazole compound, MR335, effectively counteracted the synergistic interactions between respiratory viruses and S. aureus at concentration that retained antiviral but not antibacterial activity, suggesting their synergistic cooperation and opening the way to alternative therapies that prevent bacterial superinfec...

G. Radocchia, Marta De Angelis, Maria Grazia Martina et al. · 0 citations
Review Open access Oct 2026

Phage therapy against Pseudomonas aeruginosa biofilm infections: challenges and advanced strategies

Bacteriophage therapy offers a potential solution for treating multidrug-resistant Pseudomonas aeruginosa infections, especially those involving biofilms that reduce antibiotic effectiveness. However, successful in vitro results often don not lead to consistent clinical success due to various challenges. These challeng...

Qian-He Xu, Shao-Ping Liu, J. Xi · 0 citations
Review Open access Sep 2026

Phage therapy for multidrug-resistant pulmonary infections: bridging precision matching, lung delivery, host immunity, and clinical translation

This review reframe phage therapy as a precision microbiome-modulating strategy for chronic pulmonary infections and discusses strategies that could support the development of safe, effective, and clinically applicable phage-based therapies for chronic pulmonary infections.

Ran Xiao, Yang Hao, Ya-Dong Gong et al. · 0 citations
Review Open access Sep 2026

Bacteriophage Therapy as a Viable Salvage Strategy for Extensively Drug-Resistant Gram-Negative Infections: A Narrative Review of Clinical Case Evidence, Regulatory Pathways, and the Barriers to Mainstream Adoption

Backgrounds: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter, better known as the ESKAPE group are gram-negative bacteria that are multi-drug resistant. Due to this, ESKAPE bacterial infections have become increasingly difficult to tr...

E. Engh, Angelica Rodriguez, Malaika Koreshi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.